Larry Wood - 24 May 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
24 May 2023
Net transactions value
-$250,119
Form type
4
Filing time
24 May 2023, 19:19:47 UTC
Previous filing
15 May 2023
Next filing
14 Jun 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $290,722 +6,421 +3% $45.28 220,215 24 May 2023 Direct F1
transaction EW Common Stock Sale $540,841 -6,421 -2.9% $84.23 213,794 24 May 2023 Direct F1
holding EW Common Stock 496 24 May 2023 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -6,421 -9.9% $0.000000 58,379 24 May 2023 Common Stock 6,421 $45.28 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2023.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.